{{Rsnum
|rsid=1155974
|Gene=TNMD
|Chromosome=X
|position=100598284
|Orientation=plus
|GMAF=0.4589
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=TNMD
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 43.1 | 24.6 | 32.3
| HCB | 17.8 | 20.0 | 62.2
| JPT | 29.5 | 20.5 | 50.0
| YRI | 52.4 | 27.0 | 20.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 17.8 | 20.0 | 62.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{PMID Auto
|PMID=19381347
|Title=Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in age-related macular degeneration
|OA=1
}}

{{PMID Auto
|PMID=17495183
|Title=Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study.
}}  "''The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T''."

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}